# Phase 2 carcinoma trials recruiting: 1,109 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 1,109 trials in phase 2 for carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 carcinoma trials: 1,109 rows for $55.45, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 30 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,109
- Recruiting or not yet: 1,109
- Read on: November 19, 2026

## Trials

The 25 newest of 1,109, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946848 | Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC. | Immuneering Corporation | Phase 2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), Non-Squamous Non Small Cell Lung Cancer, Metastatic Non-Small Lung Cell... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946848) |
| November 18, 2026 | NCT07944313 | Comparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung... | Quanzhou First Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Carcinoma of Lung | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944313) |
| November 17, 2026 | NCT07941609 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | AstraZeneca | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941609) |
| November 16, 2026 | NCT07940478 | A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for... | Fujian Cancer Hospital | Phase 2 | Not yet recruiting | Hepatecellular Carcinoma | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940478) |
| November 16, 2026 | NCT07939204 | A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced... | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939204) |
| November 16, 2026 | NCT07937553 | Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma. | Kidney Cancer Research Bureau | Phase 2 | Recruiting | Metastatic Chromophobe Renal Cell Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937553) |
| November 13, 2026 | NCT07936578 | Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer | Guizhou Medical University | Phase 2 | Not yet recruiting | Concurrent Chemoradiotherapy, Immunotherapy, Lung Cancer (NSCLC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936578) |
| November 13, 2026 | NCT07936422 | A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients | Centre Leon Berard | Phase 2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), Urothelial Cancer, Pan-rare Tumor With no T-DXd Approvals, Pan-frequent... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936422) |
| November 12, 2026 | NCT07933016 | QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933016) |
| November 12, 2026 | NCT07931664 | Evaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk. | The Center for Clinical and Cosmetic Research | Phase 2 | Recruiting | Cutaneous Squamous Cell Carcinoma in Situ, Facial Cutaneous Squamous Cell Carcinoma in Situ, Cutaneous Squamous Cell... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931664) |
| November 12, 2026 | NCT07931313 | PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer | Shanghai Gynecologic Oncology Group | Phase 2 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931313) |
| November 10, 2026 | NCT07928167 | Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients | Kidney Cancer Research Bureau | Phase 2 | Recruiting | Metastatic Renal Cell Carcinoma ( mRCC) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928167) |
| November 9, 2026 | NCT07925333 | Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer | Beth Israel Deaconess Medical Center | Phase 2 | Not yet recruiting | Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925333) |
| November 6, 2026 | NCT07922915 | Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Localized Clear Cell Renal Cell Carcinoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922915) |
| November 5, 2026 | NCT07919717 | NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919717) |
| November 5, 2026 | NCT07919691 | Proton Moderately Hypofractionated Radiotherapy in NSCLC Patients Unable to Tolerate Standard Concurrent Chemoradiotherapy | Ruijin Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919691) |
| November 5, 2026 | NCT07917767 | A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of... | Tang-Du Hospital | Phase 2 | Not yet recruiting | NSCLC Stage IIIA/B, NSCLC Stage II | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917767) |
| November 4, 2026 | NCT07917481 | A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma (HCC) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917481) |
| November 3, 2026 | NCT07911683 | Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma | BeOne Medicines | Phase 2 | Not yet recruiting | Hepatocellular Cancer, Liver Cancer, Hepatocellular Carcinoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911683) |
| November 2, 2026 | NCT07911449 | Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases | Cho Ray Hospital | Phase 2 | Recruiting | Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), EGFR Activating Mutation | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911449) |
| November 2, 2026 | NCT07909863 | Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909863) |
| November 2, 2026 | NCT07909265 | Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909265) |
| November 2, 2026 | NCT07908979 | Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer | Fox Chase Cancer Center | Phase 2 | Recruiting | Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908979) |
| October 29, 2026 | NCT07902713 | Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Nasopharyngeal Carcinoma (NPC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902713) |
| October 27, 2026 | NCT07896811 | Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell Carcinoma | Medical College of Wisconsin | Phase 2 | Not yet recruiting | Squamous Cell Carcinoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896811) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 73 |
| Tianjin Medical University Cancer Institute and Hospital | 39 |
| Fudan University | 27 |
| National Cancer Institute (NCI) | 23 |
| Shanghai Pulmonary Hospital, Shanghai, China | 21 |
| Peking University Cancer Hospital & Institute | 15 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 14 |
| Fujian Cancer Hospital | 13 |
| Memorial Sloan Kettering Cancer Center | 13 |
| M.D. Anderson Cancer Center | 12 |
| Hunan Province Tumor Hospital | 12 |
| Second Affiliated Hospital of Guangzhou Medical University | 11 |
| Sichuan University | 11 |
| Peking Union Medical College Hospital | 10 |
| Tang-Du Hospital | 10 |
| Shanghai Chest Hospital | 10 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 10 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 9 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 9 |
| City of Hope Medical Center | 8 |
| University Health Network, Toronto | 8 |
| Hebei Medical University Fourth Hospital | 8 |
| Shanghai Zhongshan Hospital | 8 |
| University of Texas Southwestern Medical Center | 7 |
| Zhejiang Cancer Hospital | 7 |

## By country

| Country | Trials |
| --- | --- |
| China | 503 |
| United States | 297 |
| France | 46 |
| South Korea | 41 |
| Italy | 41 |
| Spain | 39 |
| Germany | 36 |
| Canada | 34 |
| Taiwan | 32 |
| Australia | 27 |
| United Kingdom | 21 |
| Japan | 19 |
| Netherlands | 17 |
| Brazil | 13 |
| Singapore | 12 |
| Belgium | 11 |
| Israel | 11 |
| Poland | 10 |
| Hong Kong | 10 |
| Turkey (Türkiye) | 8 |
| Switzerland | 6 |
| Greece | 6 |
| Hungary | 5 |
| Puerto Rico | 5 |
| Ireland | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B oil and gas exploration and development companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-exploration-and-development-companies/united-states)
- [Towing companies in the United States](https://specstream.ai/data/businesses/towing-companies/united-states)
- [Printing companies in the United States](https://specstream.ai/data/businesses/printing-companies/united-states)
- [Lighting fixtures and equipment companies in the United States](https://specstream.ai/data/businesses/lighting-fixtures-and-equipment-companies/united-states)
- [Flour mills in the United States](https://specstream.ai/data/businesses/flour-mills/united-states)
- [Clinical laboratories in the United States](https://specstream.ai/data/businesses/clinical-laboratories/united-states)
